Search Orphan Drug Designations and Approvals
-
Generic Name: | Oprelvekin | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Neumega | ||||||||||||||||
Date Designated: | 12/17/1996 | ||||||||||||||||
Orphan Designation: | Prevention of severe chemotherapy-induced thrombocytopenia. | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, Massachusetts 02140 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | Oprelvekin |
---|---|---|
Trade Name: | Neumega | |
Marketing Approval Date: | 11/25/1997 | |
Approved Labeled Indication: | ||
Exclusivity End Date: | 11/25/2004 | |
Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-